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Abstract
Background: Heart transplantation has become standard of care for pediatric patients 
with either end-stage heart failure or inoperable congenital heart defects. Despite 
increasing surgical complexity and overall volume, however, annual transplant rates 
remain largely unchanged. Data demonstrating pediatric donor heart refusal rates of 
50% suggest optimizing donor utilization is critical. This review evaluated the impact 
of donor characteristics surrounding the time of death on pediatric heart transplant 
recipient outcomes.
Methods: An	extensive	literature	review	was	performed	to	identify	articles	focused	
on donor characteristics surrounding the time of death and their impact on pediatric 
heart transplant recipient outcomes.
Results: Potential pediatric heart transplant recipient institutions commonly receive 
data from seven different donor death-related categories with which to determine 
organ acceptance: cause of death, need for CPR, serum troponin, inotrope expo-
sure, projected donor ischemia time, electrocardiographic, and echocardiographic 
results.	Although	DITs	up	to	8	hours	have	been	reported	with	comparable	recipient	
outcomes,	most	data	support	minimizing	this	period	to	<4	hours.	CVA	as	a	cause	of	
death may be associated with decreased recipient survival but is rare in the pediatric 
population. Otherwise, however, in the setting of an acceptable donor heart with a 
normal echocardiogram, none of the other data categories surrounding donor death 
negatively impact pediatric heart transplant recipient survival.
Conclusions: Echocardiographic evaluation is the most important donor clinical 
information following declaration of brain death provided to potential recipient 
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1  | INTRODUC TION
Orthotopic heart transplantation has become standard of care for 
the pediatric population with either end-stage heart failure or inop-
erable congenital heart defects, in part due to median post-trans-
plant survival of >15 years.1	Although	VADs	have	improved	recipient	
candidacy	and	utilization	of	ABO-incompatible	donors	have	allowed	
for shorter wait times in younger infants, approximately 20% of all 
potential pediatric recipients die or are removed from the waitlist 
prior to transplantation.2,3
Pediatric cardiac surgical volume has increased markedly over 
the past decade4 while pediatric heart transplantation rates have 
largely plateaued between 500 and 600 annually.5 While some of 
this discrepancy is due to post-surgical survival rates approaching 
97%,4 a likely larger component is the nearly 50% discard rate of 
available pediatric donor hearts.6 Optimizing donor organ manage-
ment and subsequent organ utilization requires increased attention.
A	 better	 understanding	 of	 donor	 characteristic	 significance	
is critical to improve organ utilization, minimize waitlist time and 
mortality, and optimize post-transplant survival. The objective of 
this manuscript is to determine the relative impact of the following 
donor characteristics on recipient survival: cause of death, troponin 
and other cardiovascular biomarkers, ischemia/travel time, inotropic 
therapy, need for and duration of CPR, ECG findings, and echocar-
diographic findings.
2  | METHODS
This review was developed by searching the MEDLINE, Cochrane 
Library, and Web of Science databases in October 2018 with the 
help of a medical librarian. Index terms and keywords included heart 
transplantation, donor selection, tissue and organ procurement, uti-
lization, survival, waitlist, refusal, mortality, morbidity, allocation, 
ECG, echocardiogram, and pediatric. The search was limited to the 




3  | DONOR C AUSE OF DE ATH
Cause of death is commonly the first data discussed when con-
sidering a potential organ donor. Excluding donation after cardiac 
death, two major etiology categories arise: non-transferrable and 
potentially transferrable causes. Non-transferrable causes of death 
include disease mechanisms leading to irreversible brain damage 
such	as	 trauma,	 asphyxia,	 and	CVA	while	potentially	 transferrable	
causes of death are comprised of infectious diseases and malig-
nancy. The relative impact of these two categories on recipient out-
comes has received considerable attention in both the pediatric and 
adult literature.
Pathologic intracranial pressure elevations progressively de-
crease cerebral perfusion pressure and result in cerebral ischemia. 
Compensatory responses from the central nervous system result in 
supra-physiologic surges in catecholamines, sympathetic nervous 
system output, systemic vascular resistance, and both sodium and 
water retention in attempts to increase systemic pressures and 
maintain adequate cerebral perfusion.7 Unabated, this response 
progresses to cerebral ischemia, brainstem herniation, and brain 
death. During this systemic autonomic ‘storm,’ the commensurate 
increases in myocardial preload, afterload, contractility, heart rate, 
and oxygen demand are similarly profound and can produce signif-
icant ventricular dysfunction.8,9 Immediately following brainstem 
herniation, however, there is complete deactivation of the sym-
pathetic nervous system and commonly a significant injury to the 
ischemia-prone hypothalamic-pituitary axis. This shift suddenly re-
moves all the catecholamine, thyroid hormone, cortisol, vasopressin, 
and sympathetic nervous system output that were simultaneously 
straining the myocardium but maintaining end organ perfusion. The 
resulting physiology is typically characterized by decreased contrac-
tility, low systemic vascular resistance, and diabetes insipidus. When 
such patients become organ donors, they are subsequently managed 
with a variety of fluid repletion, anti-diuretic hormone, inotropes, 
vasopressors, and hormone repletion which have the potential to 
mimic the initial period of brainstem herniation. It is at this point that 
potential recipient institutions must determine whether such inju-
ries are likely to affect recipient outcomes. Further complicating this 
decision is the significant up-regulation of inflammatory cytokines 
accompanying brain death and the theoretical risk of an ischemia/
reperfusion injury, rejection and primary graft dysfunction they may 
incite immediately following transplantation.8,10
Data surrounding organ use from donors with the different types 
of non-transferrable causes of death are mixed. Several adult stud-
ies have demonstrated no association between cause of death and 
recipient/graft survival11,12	but	others	found	CVA	to	be	associated	
with worse outcomes.13	However,	the	association	between	CVA	and	
worse outcomes may be related to the increased incidence of hy-
pertension, diabetes mellitus, and tobacco use in donors dying from 
CVA.11,14 The data in pediatric and young adult populations, where 
CVA	 is	 clearly	 an	 uncommon	 cause	 of	 death,	 are	 similarly	mixed.	
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Some	studies	suggest	that	CVA	as	the	donor	cause	of	death	 is	as-
sociated with slightly higher 1-year mortality rates following trans-
plantation,15,16 but others have not.17-19 While it is plausible that the 
association	 between	 donor	 CVA	 and	 subsequent	 post-transplant	
mortality differs between adults and children, there is insufficient 
data to support this assertion. Unfortunately, there is even less data 
on	 other	 non-transferable	 causes	 of	 donor	 death.	 Although	 anec-
dotal concerns have been expressed regarding the use of donors 
dying from either smoke inhalation or drowning, there is inadequate 
data to specifically address these issues.
Transmission of pathogenic microorganisms from donor to re-
cipient is a constant source of concern for transplant centers. This 
heightened sense of awareness is further exacerbated by the recip-
ient's impending immunosuppressed status and when a pathogen 
was the donor's cause of death. However, successful transplanta-
tion of non-lymphoid organs such as the heart (as compared to lungs 
and intestines) have occurred from both pediatric and adult donors 
infected with influenza,20-22 bacterial meningitis,23 and bactere-
mia.24,25 The use of such organs, often with anti-microbial therapy in 
both	the	donor	and	recipient,	is	supported	by	the	American	Society	
of Transplantation Infectious Disease Community of Practice.26 
Despite these recommendations, however, actual utilization of such 
‘high-risk donors’ is uncommon in the pediatric population, account-
ing for only 4.1% of all pediatric transplantations.27 Considering the 
overall 50% discard rate of potential pediatric donor hearts, it is not 
surprising that acceptance of HIV- or HCV-positive donor organs is 
negligible, despite no reported cases of recipient HIV transmission 
and recent medication regimen effectively eradicating HCV in adults 
receiving organs from HCV-infected donors.28 Of note, presumably 
in part due to low transmission rates, approximately ¾ of respon-
dents in a recent international survey of pediatric heart transplant 
physicians said they would accept organs from infants exposed to 
known or suspected HIV- or HCV-infected mothers.29
Although	 far	 less	 common,	 donors	 with	 active	 or	 prior	 malig-
nancy history are another potential source for organ donation with 
disease transmission. The largest study assessing this risk evaluated 
over 8000 potential Chinese donors across all age ranges with a pos-
itive cancer history resulting in over 700 organ transplants.30 While 
there was no increased incidence of cancer transmission, they found 
significantly worse survival in heart transplant recipients from do-
nors with either hematologic or otorhinolaryngologic cancers but 
not	 with	 central	 nervous	 system	 tumors.	 A	 similar	 lack	 of	 tumor	
transmission was found in a smaller adult study including only three 
heart transplantations.31
The overall paucity of data on this subject prompted the OPTN/
UNOS	 to	 establish	 a	 Disease	 Transmission	 Advisory	 Committee	
tasked with producing guidelines on organ acceptance from donors 
with a positive malignancy history. Their document recommended 
employing a strategy of utilizing anticipated donor malignancy recur-
rence-free survival or “cure” rates as a surrogate marker for transmis-
sion risk. ‘Low risk’ would be expected from donors who are cancer 
free for at least 5 years with a cure probability of >99%; ‘interme-
diate risk’ would be those with a 90%-99% cure rate; and ‘high risk’ 
would be associated with incurable cancers, insufficient follow-up or 
cure probability <90%.32	Additional	consideration	should	be	given	to	
the metastatic potential of the donor's current or prior malignancy. 
In general, however, considering the overall limited data and near ab-
sence in the pediatric population, there is insufficient data to make 
any meaningful recommendations for the pediatric donor with a his-
tory of or active malignancy.
Donors with an unrecognized cause of death pose another spe-
cific challenge for organ transplantation. Considering the signifi-
cant electrocardiographic abnormalities associated with the brain 
death-induced electrolyte and neurohormonal changes,33 it may be 
impossible to definitively exclude a channelopathy in patients with 
unknown	 cause	of	 death.	A	 similar	 concern	 is	 the	 neonatal	 donor	
dying from SIDS. However, a small study demonstrated heart trans-
plantation from SIDS donors with normal ejection fraction had out-
comes comparable to non-SIDS donors. 34
4  | DONOR TROPONIN AND OTHER 
BIOMARKERS
Serum biomarkers of donor myocardial cell death are commonly el-
evated immediately after CPR or the catecholamine surge accom-
panying brainstem herniation. While values such as troponin and 
CK-MB are theoretically attractive due to their wide availability and 
myocardial specificity,35 it is important to understand their actual 
utility in potential donor heart selection.
Troponin-I and troponin-T are sensitive and specific to myocar-
dial injury and are routinely obtained in both pediatric and adult do-
nors. However, both isoforms can remain elevated for several days 
after an injurious event has terminated,35 significantly complicating 
their	 interpretation.	A	Eurotransplant	database	study	of	774	adult	
recipients demonstrated elevated donor troponin values, but not 
CK-MB values, to be associated with decreased 3-year survival.36 
By comparison, a single-center adult study of 159 potential heart 
donors demonstrated higher troponin values to be associated with 
an increased incidence of segmental wall motion abnormalities and 
lower ejection fractions but not with 1-year recipient survival.37 
Considering the average ejection fraction of donor hearts ultimately 
harvested for transplant was >60%, these data suggested troponin 
to be associated with acute myocardial injury but not with potential 
for recovery or recipient outcomes.
This assertion is widely supported in the adult literature. Two 
UNOS database studies of approximately 11 000 adult donors in 
which the first assessed all organs with normal ejection fractions 
and found no association between troponin values and recipient 
outcomes and a second in which 472 recipients received hearts 
with a median initial ejection fraction of 35% but normalized prior 
to transplant, similarly found no association between troponin val-
ues and recipient outcomes.38,39 Several other smaller adult studies 
have demonstrated elevated troponin values to be associated with 
left ventricular dysfunction on initial echocardiograms but not with 
recipient survival40,41 or primary graft dysfunction.42
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Only two pediatric studies have addressed the association be-
tween	myocardial	injury	biomarkers	and	recipient	outcomes.	A	large,	
single-center pediatric cohort of 182 heart transplant recipients 
demonstrated no correlation between final troponin or CK-MB values 
and recipient outcomes, though all donor echocardiograms exhibited 
normal function prior to transplant.17	An	OPTN	database	study	of	657	
heart transplant recipient <21 years of age similarly demonstrated 
no association between final donor troponin value and recipient out-
comes and instead recommended a practice of determining troponin 
trends and timing from declaration of brain death.43
Several small studies of both pediatric44 and adult donors45-47 
have failed to demonstrate the utility of BNP and NT-proBNP values 
in predicting recipient outcomes but some have shown weak correla-
tions with early myocardial dysfunction.45,47
5  | DONOR ISCHEMIA /TR AVEL TIME
DIT is defined as the time elapsed between aortic cross-clamp 
during organ procurement and coronary artery reperfusion dur-
ing heart implantation. This topic has received a great deal of at-
tention in the pediatric population and was a 2017 ISHLT registry 
report focus. The most commonly reported mean DIT in pediatric 
heart transplantation is approximately 3.5 hours; although ranges 
have extended to 10 hours, DIT >6 hours remains unusual.48-52 In 
a recent survey describing donor acceptance practices of pediatric 
heart transplant clinicians, 45% of respondents said they would 
accept a donor heart with DIT <4 hours, 22% up to 5 hours, and 
another 33% would accept up to 6 hours DIT.29 Several of the 
larger registry-based studies have noted longer DIT to be related 
to younger age,48,50,52 diagnosis of CHD,48,50,52 mechanical circu-
latory support,52 and higher acuity.48,52 Longer DIT has also been 
described	outside	of	North	America,	 though	 reporting	has	been	
variable.52
DIT >4 hours has been associated with increased intensive 
care unit and hospital stay51,52 and need for mechanical ventila-
tor support,51 but has not been demonstrated to impact rejection 
or coronary allograft vasculopathy.52 In the majority of studies, 
longer DIT is associated with primary graft failure,15,48,50,52-55 but 
not long-term graft or recipient survival.15,48-50,52,54-56 Subgroup 
analyses have demonstrated conflicting age-related effects of DIT 
on outcomes,49,50,52,54 with some concluding adolescence to be 
the highest risk period50,54 while others found worse outcomes 
in infants.52
DIT is one of the most commonly cited parameters used to de-
termine	outcomes	in	the	first	year	after	heart	transplant.	A	large	ret-
rospective cohort of pediatric heart transplant recipients (n = 4716) 
spanning over two decades demonstrated significantly improved 
1-year survival in those with DIT <3.5 hours.48 The 2017 ISHLT 
registry report found DIT >4 hours was independently associated 
with decreased survival at both 1 (87% vs 92%) and 5 years (77% vs 
82%) post-transplant, but the effect was no longer present at 10 or 
15 years; there was no long-term effect on morbidity.52
It must also be recognized that although DIT is a convenient, ob-
jective variable for evaluation, it is comprised of several confounding 
components. CHD patients following multiple sternotomies com-
monly require prolonged explant times, producing unforeseen tech-
nical challenges. Subsequent survival differences may be attributable 
to recipient factors rather than issues surrounding donor distance or 
travel time. Further, while there is an obvious direct relationship be-
tween DIT and travel time, they are not identical and the correlation 
between the two is often poor. One large retrospective adult study 
of over 14 000 transplants demonstrated that when accounting for 
DIT, transplant center volume, and both recipient and donor char-
acteristics, a 7% reduction in mortality at 30 days and a 6% reduc-
tion in mortality at 1 year were noted for every 100-mile increase 
in donor-recipient distance; there were no distance related-survival 
differences in unadjusted Kaplan-Meier curves.57 Conversely, the 
authors did find DIT to be an independent predictor for mortality at 
both 30 days and 1 year, and they hypothesized that after controlling 
for the detrimental impact of prolonged DIT, there must be a hidden, 
protective association between recipient survival and longer donor 
distances, which may be a surrogate for differences in myocardial 
cooling times or preservation practices. Certainly from the existent 
data, despite long DIT and travel distances, good outcomes can be 
achieved in both pediatric and adult recipients.49,57
Of note, some data from adult studies suggest that warm ischemic 
time (or surgical implant time) may have a more important impact 
on post-transplant outcomes than prolonged cold ischemic time.58 
However, surgical implant time is highly confounded with measures 
of recipient risk including a history of prior procedures, the need for 
concomitant procedures at the time of transplantation, and technical 
challenges with allograft implantation. No recommendations on what 
constitutes excessive warm ischemic time can be made, although it is 
prudent to reduce warm ischemia as much as practical.
A	 recent	 review	 provides	 biochemical	 comparisons	 between	
common preservation solutions and relevant preservation studies, 
but there have been no new developments in this area for a con-
siderable time.59 Hypothermia alone is unable to abolish all cellular 
damage as metabolism persists at approximately 5%-10% of normal. 
The OCS is a potential solution, allowing prolonged (up to 8 hours) 
normothermic myocardial perfusion, but is currently only suitable 
for older teenagers due to instrumentation size. This technology is 
expanding potential geographic zones for organ procurement and 
reducing the detrimental effects of DIT due to unanticipated factors 
such prolonged explant times. 60,61
6  | DONOR C ARDIOPULMONARY 
RESUSCITATION
CPR is relatively common in organ donors, either leading to their 
brain death or as a result. The challenge this history presents for re-
cipient institutions is the inherent warm ischemic time and its poten-
tial short- and long-term effects on recipient outcomes. Due to these 
theoretical concerns, hearts from CPR-positive donors are routinely 
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rejected.14,17,62 Considering CPR-positive donors comprise up to 40% 
of some pediatric series,17 determining the relative importance of this 
information is paramount to expanding the available donor pool.
A	PHTS	study	examining	the	effect	of	donor	characteristics	on	
outcomes of 3149 recipients found no donor characteristics, includ-
ing presence or absence of donor CPR, to have a negative effect 
on overall recipient outcomes.50 Likewise, a 2011 study of pediatric 
heart transplant recipients using the UNOS database found no ef-
fect of donor CPR on recipient survival at 30 days, 1, and 5 years 
post-transplant.63	A	recent	systematic	review	came	to	similar	con-
clusions, supporting consideration of transplant after donor CPR, 
citing these and three older studies specifically relevant to pediatric 
heart transplantation.64 Data from several adult studies also support 
the use of donor hearts without consideration of CPR status.36,65,66
Interestingly, a single-institution study from France actually found 
higher 5- and 10-year survival in their adult heart transplant recipients 
who received CPR-positive donor hearts, prompting the authors to 
suggest donor myocardial ischemic preconditioning may have salutary 
effects.67 This has been similarly demonstrated in a pediatric cohort.63 
It should be noted, however, that many of the studies promoting the 
use of CPR-positive donors also demonstrate normal LVEF in the en-
tire cohort,17,38,63,67 suggesting that echocardiographic measures of 
cardiac function are a more important factor in recipient outcome 
than whether or not CPR occurred.16 Therefore, in the absence of 
data suggesting a negative association between donor CPR and recip-
ient outcomes, its history, regardless of duration, should not preclude 
transplantation of an otherwise acceptable donor heart.50,62-64,67
7  | DONOR INOTROPE E XPOSURE
Following brainstem herniation, the body's neurohormonal response, 
designed to maintain cerebral perfusion pressure, is suddenly trun-
cated. The result is a loss of sympathetic and adrenergic output pro-
ducing a catecholamine, afterload, and preload deficient state that 
must be mitigated if organs are to be preserved for donation. Inotrope 
infusions and fluid resuscitation comprise the majority of interventions 
undertaken to maintain adequate organ perfusion, but could theo-
retically induce permanent donor myocardial injury when used exces-
sively. This concern has led some to define inotrope supported donor 
hearts as ‘marginal’68 and is a common indication for organ refusal.69 
Whether donor inotrope exposure actually alters pediatric heart trans-
plant recipient outcomes is therefore of significant interest.
Studies suggesting a negative impact of donor inotropic expo-
sure	are	rare.	An	adult	study	assessing	high	(>10	mcg/kg/min)	verses	
low dose (<10 mcg/kg/min) donor dopamine exposure on recipient 
outcomes found a non-significant trend toward endomyocardial bi-
opsy evidence of myocyte necrosis in the high-dose group but no 
differences in donor ejection fraction, post-transplant ICU dura-
tion or 5-year recipient survival.70	A	PHTS	model	predicting	1-year	
post-transplant survival using recipient or donor factors demon-
strated a weak association between lower survival and ‘higher donor 
vasoactive support,’ but only in recipients with CHD and only in 
a model that included both donor and recipient data.18 The 2017 
ISHLT registry report cited donor inotrope use to be associated 
with decreased 1-year post-transplant survival in recipients <1 year, 
but without mention of number of inotropes, dosing, or ventricular 
function.52
By comparison, the majority of studies assessing donor inotrope 
use have either shown no association with post-transplant out-
comes50,68,70-73 or beneficial effects.39,71,74 PHTS data of over 3000 
children showed no correlation between donor inotrope exposure 
on recipient 1-year survival, even when differentiated by high verses 
low dose or when combined with need for CPR, head trauma as 
cause of death and prolonged ischemic time; further, donor expo-
sure to hormonal therapy was associated with improved recipient 
outcomes.50	A	large	single-center	study	of	192	pediatric	recipient/
donor pairs evaluating donor exposure to high dose (>5 mcg/kg/min), 
low dose, and no dopamine demonstrated no difference in 1-year 
survival and a significantly decreased incidence of post-transplant 
right heart failure when donors received dopamine.71 Several adult 
studies have also demonstrated inotropic support to be associated 
with either higher74 or similar36 3-year graft survival and without dif-
ference in primary graft failure.72-74
A	particular	challenge	is	use	of	donor	hearts	with	previously	de-
pressed left ventricular function receiving inotropic support. These 
characteristics comprise the most common indications for pediat-
ric organ refusal68,69 but over the past two decades, acceptance of 
such organs has increased 30% without any difference in recipient 
outcomes.69	 A	 large	UNOS	database	 study	 of	 over	 11	000	 adults	
demonstrated no difference in primary graft failure rates, 30-day, 
1-, 3- or 5-year survival between those who received donor hearts 
with early dysfunction (average ejection fraction 35%) requiring ino-
tropic support to achieve normal preimplant function or those with 
normal function throughout the entire preimplant period.39 These 
data suggest concerns that donor inotropic support can temporarily 
augment donor systolic function and misrepresent eventual recipi-
ent outcomes are unfounded.
One plausible explanation for this lack of association between 
recipient outcomes and donor inotrope exposure, particularly in 
hearts initially demonstrating left ventricular dysfunction, is the 
commensurate	component	of	time	after	brain	death.	As	with	many	
acute, non-ischemic myocardial insults (ie, myocarditis), time and 
supportive medical management are commonly adequate to allow 
complete recovery. This assertion is supported by several adult stud-
ies demonstrating longer time from declaration of brain death is as-
sociated with improved rates of primary graft failure.39,73
8  | DONOR ELEC TROC ARDIOGR AM
ECG evaluation of a potential heart donor is nearly universally pro-
vided to recipient institutions to allow an assessment of prior or 
ongoing myocardial ischemia, intrinsic channelopathies, accessory 
pathways, or pathologic hypertrophy. However, no pediatric and 
only a few adult studies exist to guide the clinician on donor allograft 
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acceptance based on these findings. This process is particularly chal-
lenging as ECG changes associated with brain death, the most com-
mon indication for organ donation, are well documented to include 
ST segment depression and elevation, T wave inversion, U waves, 
QT prolongation, and LVH.13,75,76 Considering these changes are at-
tributed to the transient autonomic storm and electrolyte abnormal-
ities that accompany brain death,13,75,76 their impact on long-term 
recipient survival is uncertain.
The largest study to address this issue examined 980 adult 
donor ECGs, of which 51% were noted to have one or more ab-
normalities defined as ectopy/arrhythmia, conduction delay, ven-
tricular hypertrophy, chamber enlargement, pathologic Q waves, 
ST segment changes, or inverted T waves.75 Pathologic Q waves 
had a high specificity, though low sensitivity, for the detection 
of reduced LVEF and regional wall motion abnormalities on echo-
cardiogram.	 Atrial	 or	 ventricular	 ectopy	 and	 conduction	 delays	
were rare. LVH, considered a relative contraindication to heart 
transplantation in adult literature77,78 due to a perceived risk of 
primary graft dysfunction, particularly when paired with pro-
longed DITs,79 was present in 8%.75 This was significantly more 
common in donors who died of cerebrovascular causes as com-
pared to traumatic brain injury or anoxia and was hypothesized 
to be secondary to myocardial edema. Corrected QT (QTc) was 
>480	ms	in	21%	and	>500	ms,	in	15%.	Although	no	analyses	were	
performed regarding recipient outcomes, aside from PR and QRS 
intervals there were no associations between ECG findings and 
organ utilization.
Another	 adult	 study	 evaluated	 the	 association	 of	 donor	 QTc	
>500 ms on 1-year post-transplant recipient outcomes.76	At	 study	
conclusion, donor QTc prolongation was not associated with recip-
ient survival or persistence of QTc prolongation. Of interest, how-
ever, was a significant association between donor QTc prolongation 
and increased risk of cardiac allograft vasculopathy which was hy-
pothesized to be related to proinflammatory cytokines released at 
the time of brain death.
Given brain death's transient effect on the myocardium, it is rea-
sonable to repeat an ECG after periods of hemodynamic stability,75 
particularly when initial studies are significantly abnormal. With the 
available literature to date, there is little additional guidance offered 
from the ECG outside of an echocardiogram, as no independent ECG 
components have proven to be predictive of graft outcomes.13,36,75,76 
This must, however, be interpreted in the context of a known cause 
of death. Given that cerebrovascular causes of death result in similar 
abnormal ECG findings, the donor cause of death needs to be clar-
ified to help rule out intrinsic conduction abnormalities, such as a 
channelopathy. 13
9  | DONOR ECHOC ARDIOGR APHIC 
E VALUATION
All	 donor	 information	 provided	 to	 potential	 pediatric	 recipient	 in-
stitutions is intended to allow an estimate of that heart's short 
and long-term functional longevity. Cause of death and need for 
CPR describe prior finite events associated with exacerbations 
of catecholamine, cytokine, and sympathetic nervous system up-
regulation. Serum biomarkers of myocardial injury measure the im-
mediate quantity of cellular injury associated with these prior events 
and their downward trend describes the time course of insult ces-
sation. Need for donor inotrope therapy is commonly required to 
offset the neurohormonal void that develops following brainstem 
herniation and ECG changes are typically reflective of myocardial 
strain and electrolyte disarray. Donor ischemia time is a predict-
able parameter largely determined by donor and recipient locations. 
Echocardiographic evaluation, however, is arguably the most repre-
sentative measure of current donor left ventricular function and po-
tentially the most important data available to any potential recipient 
institution.
Numerous studies have demonstrated decreased utilization of 
potential donor hearts with echocardiographic evidence of ejection 
fractions <50%,6,17,19,68,69,80 and ISHLT guidelines have similarly rec-
ommended refusal of donor hearts with ejection fractions <40%.78 
This practice has been supported by several pediatric16,17 and adult81 
studies suggesting higher rates of graft failure following transplant 
of hearts with ejection fractions <50% and a recent pediatric donor 
utility survey demonstrating half of all respondents would decline an 
otherwise acceptable organ with an ejection fraction <50%.29
Conversely, a larger number of pediatric and adult studies have 
demonstrated comparable recipient outcomes following transplan-
tation of hearts with ejection fractions <50%19,36,39,69,82 and/or with 
evidence of segmental wall motion abnormalities.36,82 This differ-
ence may be secondary to increased time intervals between initial 
echocardiograms demonstrating poor function (oftentimes shortly 
after herniation) and preharvest myocardial function, (whether doc-
umented by echocardiogram or not) with the time interval allowing 
for myocardial recovery from the neurologic death-induced “cate-
cholamine storm.”8 Several pediatric19 and adult39,83 studies have 
documented the phenomenon of significantly improved function 
between initial and final (preharvest) echocardiogram following a 
combination of time and medical management using inotropic and/
or hormonal therapy. These data support serial echocardiographic 
evaluation of potential donor hearts to assess for functional changes 
following the systemic response to brain death.
It is important to note a large number of studies in this docu-
ment have demonstrated no difference in recipient/graft outcomes 
following transplantation with donor hearts based on their his-
tory of CPR,14,16,17,38,63,67 troponin elevations,16,38,43,66,67 inotro-
pic infusion exposure,43,70,71 ischemia time,14,16,38,43,67 or cause of 
death,8,11,16,34,66,67,70,84 have been in the setting of normal ejection 
fractions. This suggests that donor ejection fraction may be the 
most important information available to a potential recipient institu-
tion, a sentiment mirrored by others.13
Lastly, two pediatric studies have demonstrated concerning 
disparity in image interpretation between the ‘local,’ donor site car-
diologist and central laboratory evaluations of left ventricular func-
tion.85,86 Considering the relative importance of echocardiographic 
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